The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Presumably their collection kits don’t neutralise the virus?
The risk / opportunity ratio on this share is now just beautiful. Feel sad for anyone selling but I’ll happily take your shares.
Is this the basis of SaturnPass? Perhaps this is the reason for the adhoc initial website. They didn’t want to give away BBI involvement.
Thanks for the pointers Ophidian.
On page 10, spanning both the Desired and Acceptable columns: “Evidence that live virus is deactivated early in the process.“
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/895745/TPP_Point_of_Care_SARS-CoV-2_Detection_Tests.pdf
Many thanks for this excellent contribution Ophidian.
Could you possibly elaborate on what makes you think the ‘Optimise LFD for viral inactivation’ step has taken place? Is there any hard evidence for it?
Dunning Kruger in full effect:
https://en.m.wikipedia.org/wiki/Dunning–Kruger_effect
Thank you Ophidian for showing these idiots the door. Tell them to find another boozer for a lock-in. Anyone for a game of darts?
It takes strong leadership to only release the test when it is ready and proven. This will pay dividends for us all in the long term. Reputation is everything in the sector. Be patient, it will come and when it does, you can see the huge swell of demand that awaits us.
This is the UK Gov rushing in once again. The Guardian are not impressed:
https://www.theguardian.com/world/2020/aug/03/coronavirus-90-minute-tests-to-be-provided-in-care-homes-and-hospitals
But some experts were surprised by the government’s decision, saying the particular tests were not well-known. No data had been published concerning their evaluation. The government had made mistakes in buying tests that turned out to be sub-standard in the past, they said.
“Repeatedly through the pandemic the government has raced ahead purchasing tests on the basis of manufacturer’s claims, and have found later when independent studies are done that the tests do not have adequate performance for use in the NHS,” said Professor Jon Deeks from Birmingham University, part of a team who have been evaluating tests of this sort.
Advertisement
“We would hope that the government would wait for proper evaluations, and consider the scientific evidence for all available tests before signing further contracts. The mistakes made in test purchasing have wasted millions of pounds as well as put lives at risk.”
https://youtu.be/2o9tF4bOAVk
AS told us in this video:
“We have some highly specific Affimer reagents to the SACS-COV-2 spike protein that also have a high binding affinity. So, we’re aiming for a high performance test both with the lateral flow test we are developing with Cytiva and the laboratory test we are developing with Adeptrix. “
I have watched this video previously but going back to it now, does it in fact actually tell us that sensitivity will be high for the LFD? “High binding affinity” surely equals high sensitivity?
Also, the word “so” feels important. It is because of what AS knows about the Affimer reagents that he is stating the aim of high performance.
The lab test of course has already been described as ‘gold standard’ by AS in a recent RNS. How about one next week calling the LFD the same?
Apologies if everyone else fully got this straight off!
Klaus was waiting outside in the car on double yellows. Was mumbling for Al to hurry up which made me smile. Mumbled something else I didn't quite hear properly. Was either ‘sick bugger’ or ‘six bagger’. Hoping for the later.
Some here may not believe this but the wife and I were in the Wetherby Whaler earlier. Haddock and chips (plus scraps) all round. An excellent chippy.
Who walks in? No less than the big Al himself. Ordered a battered saveloy and chips (surprising). We got talking about Avacta naturally. Just as we were heading off he picked out a can of 7-Up from the fridge and i could swear he winked at me. I nearly dropped my mushy peas!
DYOR etc.
I think my point is that the app isn’t necessarily just sprinkles. There is a chance it could underpin the whole testing regime, especially if we don’t hit exceptional sensitivity.
If the test has high sensitivity:
16 sticks over 4 months at £240 a pack.
If the test is lower sensitivity:
32 sticks over 4 months at £240 a pack.
Still viable, still ensures you can confidently prove you are likely to be Covid free, just a bit more effort for the punter.
Keep the app up to date whilst on holiday and beyond and you can come back to the UK without quarantine.
What am I missing?
Would also solve any sensitivity issue by ensuring the frequency of testing.
Again this is imagineering (for fun whilst we wait).
You have to test and upload a result once a week to keep your virtual C-19 Passport valid. Medusa sell the LFD in packs of say 16 (4 months worth) for £240. The app is a free download.
Just imagineering at this point. Seems to work as a concept though.
To be clear, both the QR Code and the encrypted key would need to be unique.
A team of app developers are probably working weekends to get it out on time. :-)
Patents are worth very little in a lot of cases as you say. You can get one for most things if you make it narrow enough.
Here is my guess at this. It needs to be something that makes the process simple to use and difficult to fake.
Each LFD contains a unique QR Code printed on it at manufacture. The QR Code would contain an encrypted key.
When using the LFD you do the test then use the SaturnPass app to photograph the stick. This does four things:
1. Reads the result of the test.
2. Reads the QR Code.
3. Checks the encrypted key held in the QR Code with the SaturnPass servers. Specifically - is it a valid key and has it been used before?
4. If all is well at step 3, the result of the test is stored in the app and on the SaturnPass servers (if you have given permission for this - probably optional).
Wonder if I’ll turn out to be right?
From the medusa19 website:
“ Longer-term, the Group’s objective is to entrench itself within the global medical supply chain, serving businesses and consumers worldwide with a range of tests and solutions that identify a variety of conditions, supporting health, well-being and business continuity throughout the globe. ”
So, “tests and solutions”. Tests we understand but “solutions”? Perhaps this is eluding to an app based test tracker. Go read the paragraph again. Does it give something away?
Antibody test.
A N T I B O D Y
Google it.